HDP1.F Arrowhead Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
42.45 EUR
Close of Nov 12, 2026
32.68 80.72
Market cap
EUR 6.00B
P/E
-
P/B
15.01x
ROE
-84.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is HDP1.F undervalued?

Graham number

The Graham number of Arrowhead Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Arrowhead Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Arrowhead Pharmaceuticals Inc yet.

Arrowhead Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also …

Full company profile